|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Conducted
|
|
gptkbp:collaborations
|
Academic institutions
Research organizations
|
|
gptkbp:community_health
|
Contributes to
|
|
gptkbp:community_impact
|
gptkb:Significant
|
|
gptkbp:community_outreach
|
Engaged
|
|
gptkbp:developed_by
|
gptkb:United_States
|
|
gptkbp:distribution_channels
|
Hospitals
Clinics
Pharmacies
|
|
gptkbp:education_and_awareness
|
Promoted
|
|
gptkbp:funding
|
Allocated
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Merck Vaccines
|
|
gptkbp:includes
|
gptkb:Pro_Quad
gptkb:MMR_II
gptkb:Zostavax
gptkb:Varivax
gptkb:Gardasil
|
|
gptkbp:innovation
|
Continuous
|
|
gptkbp:invention
|
Held
|
|
gptkbp:is_effective_against
|
gptkb:High
|
|
gptkbp:is_vulnerable_to
|
Intramuscular
Oral
Subcutaneous
Subunit
Inactivated
Cold chain required
m RNA
Conjugate
Live attenuated
Recombinant
|
|
gptkbp:marketed_as
|
Merck brand
|
|
gptkbp:partnerships
|
gptkb:Non-profit_organizations
Government agencies
Public health organizations
|
|
gptkbp:produced_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:production_location
|
Global
|
|
gptkbp:provides_guidance_on
|
Followed
|
|
gptkbp:regulatory_compliance
|
Required
|
|
gptkbp:research_and_development
|
Ongoing
|
|
gptkbp:research_focus
|
Infectious diseases
Viral diseases
Bacterial diseases
|
|
gptkbp:safety_features
|
Established
|
|
gptkbp:side_effect
|
Possible
|
|
gptkbp:supply_chain
|
gptkb:complex
|
|
gptkbp:target_audience
|
gptkb:children
Adults
Elderly
|
|
gptkbp:used_for
|
Preventing diseases
|
|
gptkbp:bfsParent
|
gptkb:Merck_Healthcare
|
|
gptkbp:bfsLayer
|
5
|